Ixazomib is a proteasome inhibitor used in the treatment of multiple myeloma. However, during the manufacturing process, unwanted substances or impurities may be formed. These impurities can affect the purity, potency, and safety of the final product. Therefore, it is crucial to identify and control the levels of these impurities to ensure the quality and efficacy of Ixazomib. Various analytical techniques are used to detect and quantify these impurities, including HPLC, LC-MS, and NMR spectroscopy.
